PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cutting Edge Information (CEI)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch - Market access priorities shift from market research to health economics research during the launch process, finds Cutting Edge Information - CuttingEdgeInfo.com
Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch

 

NewswireToday - /newswire/ - Durham, NC, United States, 2013/06/20 - Market access priorities shift from market research to health economics research during the launch process, finds Cutting Edge Information - CuttingEdgeInfo.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pharmaceutical companies focus their attention on market research in Phase 3a to market approval, and on health economics and outcomes research (HEOR) from launch to six months post-launch, according to a study published by Cutting Edge Information.

Market access is instrumental in informing future brand strategies. The study,“Launching Pharmaceutical Brands: Formulas for Commercialization Success,” found that between market approval and launch, market research and HEOR resources even out, receiving 11% and 10% of the average budget, respectively. Market access categories’ financial support lessens from launch to six months post-launch. During that timeframe, HEOR becomes the market access priority with 9% of the average total budget while market research receives only 6%.

“Time and again, interviewed executives emphasized the importance of understanding the markets when aiming to achieve a quick sales uptake,” said David Richardson, research manager at Cutting Edge Information. “However, once they achieve this understanding, pharmaceutical companies are free to focus on other important market access categories.”

Surveyed brands focused on market access throughout the commercialization and launch process, though specific attentions changed from Phase 3a to post-launch. Pharmaceutical companies must support many different commercialization efforts to ensure a brand’s successful launch.

During the early stages of commercialization Phase 3a to market approval surveyed companies allocate an average of 17% of their budget to market research. This category is the highest financial priority among market access concerns. At the same time, HEOR receives only 6% of the average budget, less than both market research and pricing and reimbursement concerns.

Cutting Ede Information’s study,“Launching Pharmaceutical Brands: Formulas for Commercialization Success," explores 15 individual pharmaceutical brands’ launches in the US, Canada, Europe and Asia. Use this report to:

• Plan budgets and win necessary resources for commercialization and launch;
• Know when and how much to invest in specific areas of advertising and promotion, market access, decision support and medical affairs;
• Use benchmarking data to identify investment levels and patterns among comparable brands.

For the latest research on global pharmaceutical marketing and brand launch strategy, contact Cassie Demeter.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cutting Edge Information (CEI)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Cassie Demeter - CuttingEdgeInfo.com 
919-403-6583 cassie_demeter[.]cuttingedgeinfo.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cutting Edge Information (CEI) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cutting Edge Information (CEI) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)